Berenguer, JuanDíez, CristinaMartin-Vicente, MariaMicán, RafaelPérez-Elías, María-JesúsGarcía-Fraile, Lucio JesúsVidal, FranciscoSuárez-García, InésPodzamczer, DanielDel Romero, JorgePulido, FedericoIribarren, José AntonioGutiérrez, FélixPoveda, EvaGalera, CarlosIzquierdo Miguel, RebecaAsensi, VíctorPortilla, JoaquínLópez, Juan CArribas, José RMoreno, SantiagoGonzález-García, JuanResino, SalvadorJarrin Vera, Inmaculada2022-05-062022-05-062021-11Clin Microbiol Infect. 2021 Nov;27(11):1678-1684.http://hdl.handle.net/20.500.12105/14295Objectives: We aimed to assess the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and factors associated with seropositivity and asymptomatic coronavirus disease 2019 (COVID-19) among people with HIV (PWH). Methods: This was a cross-sectional study carried out within the cohort of the Spanish HIV Research Network. Participants were consecutive PWH with plasma collected from 1st April to 30th September 2020. We determined SARS-CoV-2 antibodies (Abs) in plasma. Illness severity (NIH criteria) was assessed by a review of medical records and, if needed, participant interviews. Multivariable logistic regression analysis was used to identify predictors of seropositivity among the following variables: sex, age, country of birth, education level, comorbidities (hypertension, chronic heart disease, diabetes mellitus, non AIDS-related cancer, chronic kidney disease, cirrhosis), route of HIV acquisition, prior AIDS, CD4þ cell count, HIV viral load, nucleoside/nucleotide reverse transcriptase inhibitor (N [t]RTI) backbone, type of third antiretroviral drug, and month of sample collection. Results: Of 1076 PWH (88.0% males, median age 43 years, 97.7% on antiretroviral therapy, median CD4þ 688 cells/mm3 , 91.4% undetectable HIV viral load), SARS-CoV-2 Abs were detected in 91 PWH, a sero prevalence of 8.5% (95%CI 6.9e10.3%). Forty-five infections (45.0%) were asymptomatic. Variables inde pendently associated with SARS-CoV-2 seropositivity were birth in Latin American countries versus Spain (adjusted odds ratio (aOR) 2.30, 95%CI 1.41e3.76, p 0.001), and therapy with tenofovir disoproxil fumarate plus emtricitabine (TDF/FTC) versus tenofovir alafenamide (TAF)/FTC as the N(t)RTI backbone (aOR 0.49, 95%CI 0.26e0.94, p 0.031). Conclusions: Many SARS-CoV-2 infections among PWH were asymptomatic, and birth in Latin American countries increased the risk of SARS-CoV-2 seropositivity. Our analysis, adjusted by comorbidities and other variables, suggests that TDF/FTC may prevent SARS-CoV-2 infection among PWH.engVoRhttp://creativecommons.org/licenses/by-nc-nd/4.0/COVID-19HIVSARS-CoV-2SerologySeroprevalenceAttribution-NonCommercial-NoDerivatives 4.0 Internacional3418620927111678-168410.1016/j.cmi.2021.06.0231469-0691Clinical Microbiology and Infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseasesopen access